Jason Raleigh Nunn bought $15.0M of Zenas BioPharma (ZBIO)
Executed Sep 16 2024, disclosed Sep 16 2024, the same day.
Over the 21 trading sessions from the disclosed entry session (Sep 16 2024), the stock returned +4.9% (delay-adjusted); from the execution session (Sep 16 2024), +4.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jason Raleigh Nunn (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Zenas BioPharma, Inc. (ZBIO). Across 1 priced purchase filing, the average 21-session return was +23.8% from execution and +35.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of ZBIO (63,158 sh × $19.00, as filed), executed Oct 9 2025.
Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→63,158 sh × $19.00
Exec Oct 9 2025
Filed Oct 14 2025 · 5:16 PM ET